Kenya expands HIV prevention options as Lenacapavir rollout begins Thursday
Kenya is set to begin the national rollout of the long-acting HIV prevention injection Lenacapavir on Thursday, February 26, 2026, as the country steps up efforts to cut new infections to zero by 2030.
However, health experts say not everyone at risk of contracting HIV will qualify for the jab, which will be administered only to individuals who test negative and who have not had potential exposure to the virus within the past 72 hours.
The experts have also cautioned clients to disclose any other medication they are using — including sexual performance enhancement drugs and tuberculosis treatment — to healthcare providers, warning of potentially harmful drug interactions.
Kenya recorded just over 19,000 new HIV infections in 2024, translating to about 52 new infections every day, figures officials hope to reduce to zero by 2030.
Lenacapavir, a form of long-acting pre-exposure prophylaxis (PrEP), will be offered as an additional prevention option alongside existing methods such as oral PrEP and Cabotegravir, officials said.
Studies show that when administered correctly, Lenacapavir is up to 96 per cent effective in preventing HIV. Eligible clients will receive two injections, administered once every six months.
Kenya has outlined a three-phase rollout of the drug. The first phase will cover 15 counties selected based on high rates of new infections and overall HIV burden, followed by a second phase covering another 15 counties, before a final phase targeting 17 counties.
The rollout is expected to expand access to HIV prevention services, particularly for individuals who may struggle with daily oral medication.
